Biogen & Abbvie’s Zinbryta treatment for MS granted marketing authorisation by EC

Biogen and AbbVie have announced that the European Commission has given marketing authorisation for Zinbryta, to be used as treatment of adult patients with relapsing forms of multiple sclerosis. “With the approval of Zinbryta in the European Union, we are providing a much needed treatment option for people living with MS,” added Michael Severino, M.D.,

Continue Reading